Idiopathic pulmonary fibrosis: Moving forward

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Richeldi, Luca ^a,b,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b University Hospital Southampton NHS Foundation Trust   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Epidemiology; High resolution computed tomography; Idiopathic pulmonary fibrosis; Interstitial lung disease; Patient reported outcomes; Staging

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; COUNSELING; DISEASE COURSE; FIBROGENESIS; FIBROSING ALVEOLITIS; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE ORGANIZATION; HUMAN; LUNG CANCER; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; GENETICS; INCIDENCE; INTERSTITIAL LUNG DISEASE; PROGNOSIS;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; LUNG DISEASES, INTERSTITIAL; PROGNOSIS;

EID: 84959872482     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0481-6     Document Type: Article

References (11)

1. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46:795-806.
2. Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3-e19.
3. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.
4. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92.
5. Mathai SK, Yang IV, Schwarz MI, Schwartz DA. Incorporating genetics into the identification and treatment of idiopathic pulmonary fibrosis. BMC Med. 2015. doi: 10.1186/s12916-015-0434-0.
6. Bellaye P-S, Kolb M. Why do patients get IPF? Current concepts in pathogenesis of pulmonary fibrosis. BMC Med. 2015. doi: 10.1186/s12916-015-0412-6.
7. Vancheri C. IPF and cancer: do they really look similar? BMC Med. 2015. doi: 10.1186/s12916-015-0478-1.
8. Johannson KA, Ley B, Collard HR. Models of disease behaviour in idiopathic pulmonary fibrosis. BMC Med. 2015. doi: 10.1186/s12916-015-0403-7
9. Russell A-M, Sprangers MAG, Wibberley S, Snell N, Rose DM, Swigris JJ. The need for patient-centered clinical research in IPF. BMC Med. 2015. doi: 10.1186/s12916-015-0475-4.
10. Fregonese L, Eichler I. The future of the development of medicines in IPF. BMC Med. 2015. doi: 10.1186/s12916-015-0480-7
11. Walsh SLF, Wells AU, Sverzellati N, Deveraj A, Von der Thusen J, Yousem SA, et al. Relationship between fibroblastic focus profusion and high resolution CT morphology in fibrotic lung disease. BMC Med. 2015. doi: 10.1186/s12916-015-0479-0.